[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201400423A1 - Фармацевтические препараты и их применение при лечении половой дисфункции у женщин - Google Patents

Фармацевтические препараты и их применение при лечении половой дисфункции у женщин

Info

Publication number
EA201400423A1
EA201400423A1 EA201400423A EA201400423A EA201400423A1 EA 201400423 A1 EA201400423 A1 EA 201400423A1 EA 201400423 A EA201400423 A EA 201400423A EA 201400423 A EA201400423 A EA 201400423A EA 201400423 A1 EA201400423 A1 EA 201400423A1
Authority
EA
Eurasian Patent Office
Prior art keywords
women
sexual dysfunction
relates
treatment
application
Prior art date
Application number
EA201400423A
Other languages
English (en)
Other versions
EA034539B1 (ru
Inventor
Ян Йохан Адриан Тейтен
Йоханнес Мартинус Мария Блумерс
Original Assignee
Эмоушнл Брэйн Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмоушнл Брэйн Б.В. filed Critical Эмоушнл Брэйн Б.В.
Publication of EA201400423A1 publication Critical patent/EA201400423A1/ru
Publication of EA034539B1 publication Critical patent/EA034539B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к области женской половой дисфункции. В частности, оно относится к влиянию комбинации тестостерона или его аналога и тадалафила на половое здоровье женщин, пациенток с женской половой дисфункцией (такой как нарушение полового возбуждения у женщин (НПВЖ; FSAD) или нарушение сексуального желания у женщин (НСЖЖ; FSDD)). Кроме того, оно относится к влиянию комбинации тестостерона или его аналога и соединения, способного, по меньшей мере, частично подавлять сокращение гладкой мускулатуры, например соединения, способного, по меньшей мере, частично подавлять адренергический тонус. Изобретение, кроме того, раскрывает иную комбинированную терапию для лечения женской половой дисфункции.
EA201400423A 2005-11-11 2006-11-10 Фармацевтическая композиция, включающая тадалафил и тестостерон или его аналог EA034539B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05077577A EP1790343A1 (en) 2005-11-11 2005-11-11 Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction

Publications (2)

Publication Number Publication Date
EA201400423A1 true EA201400423A1 (ru) 2015-01-30
EA034539B1 EA034539B1 (ru) 2020-02-18

Family

ID=36118697

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200801310A EA021540B1 (ru) 2005-11-11 2006-11-10 Применение комбинации тестостерона и тадалафила для лечения половой дисфункции у женщин
EA201400423A EA034539B1 (ru) 2005-11-11 2006-11-10 Фармацевтическая композиция, включающая тадалафил и тестостерон или его аналог

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200801310A EA021540B1 (ru) 2005-11-11 2006-11-10 Применение комбинации тестостерона и тадалафила для лечения половой дисфункции у женщин

Country Status (27)

Country Link
US (3) US9333203B2 (ru)
EP (2) EP1790343A1 (ru)
JP (2) JP2009515875A (ru)
KR (5) KR20170029011A (ru)
CN (2) CN103083325B (ru)
AU (1) AU2006312373B2 (ru)
BR (1) BRPI0618385A2 (ru)
CA (1) CA2629364C (ru)
CY (1) CY1122051T1 (ru)
DK (1) DK1965802T3 (ru)
EA (2) EA021540B1 (ru)
ES (1) ES2744206T3 (ru)
HK (1) HK1128226A1 (ru)
HR (1) HRP20191544T1 (ru)
HU (1) HUE045846T2 (ru)
IL (1) IL191280A (ru)
LT (1) LT1965802T (ru)
ME (1) ME03499B (ru)
NO (3) NO342986B1 (ru)
NZ (1) NZ567963A (ru)
PL (1) PL1965802T3 (ru)
PT (1) PT1965802T (ru)
RS (1) RS59268B1 (ru)
SI (1) SI1965802T1 (ru)
UA (2) UA97101C2 (ru)
WO (1) WO2007055563A2 (ru)
ZA (2) ZA200804443B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1750766T3 (pl) 2004-05-11 2013-12-31 Eb Ip Lybrido B V Preparaty farmaceutyczne i ich zastosowania do leczenia zaburzeń seksualnych u kobiet
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CA2835911C (en) * 2011-05-13 2022-08-30 Trimel Biopharma Srl Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
WO2012156820A1 (en) * 2011-05-15 2012-11-22 Trimel Pharmaceuticals Corp. Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism
FR2999086B1 (fr) * 2012-12-10 2015-04-10 Ethypharm Sa Composition orale et/ou buccale sous forme de film fin d'un principe actif faiblement soluble, son procede de preparation et son utilisation
US10238593B2 (en) 2014-11-14 2019-03-26 Follea International System and method for preventing alopecia
EP3307280B1 (en) 2015-06-11 2021-10-27 Rejoy Treatment of sexual dysfunction
US11717495B2 (en) * 2020-03-16 2023-08-08 Vella Bioscience, Inc. Use of cannabinoids in treating anti-depressant-induced female sexual dysfunction

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3976776A (en) * 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
DK169601B1 (da) * 1983-10-17 1994-12-19 Duphar Int Res Piperazinderivater og farmaceutisk præparat indeholdende et sådant derivat, samt piperazinderivater med mellemproduktanvendelse
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4640921A (en) * 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US5015646A (en) * 1987-08-28 1991-05-14 Bristol-Myers Squibb Co. Pharmaceutically useful polymorphic modification of buspirone
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
US5447912A (en) 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
RU2152787C2 (ru) 1994-06-02 2000-07-20 Дан Рига Лекарство против стресса, против снижения уровня активности и против старения и способ его получения
BR9408581A (pt) 1994-06-02 1997-08-26 Dan Riga Medicamento anti-tens o anti-incapacitação e anti-envelhecimento e processo para a sua produção
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
AU4844396A (en) 1995-03-01 1996-09-18 Kyowa Hakko Kogyo Co. Ltd. Imidazoquinazoline derivatives
DE814775T1 (de) 1995-03-14 1998-06-25 Vivus Inc Methode und kit zur verhütung erektiler dysfunktion
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
CA2219082A1 (en) 1995-05-15 1996-11-21 Beth Israel Deaconess Medical Center, Inc. Use of dihydrotestosterone compounds for treating male sexual dysfunction
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US5972614A (en) * 1995-12-06 1999-10-26 Genaissance Pharmaceuticals Genome anthologies for harvesting gene variants
WO1997044466A1 (en) * 1996-05-17 1997-11-27 Endorecherche, Inc. Characterization and use of an isolated uridine diphospho-glucuronosyltransferase
US6242198B1 (en) 1996-07-25 2001-06-05 Cambridge Neuroscience, Inc. Methods of treatment of eye trauma and disorders
ATE315931T1 (de) * 1997-06-23 2006-02-15 Cellegy Pharma Inc Microdosistherapie von gefässbedingten erscheinungen durch no-donoren
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US20020013304A1 (en) 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
WO1999021562A1 (en) 1997-10-28 1999-05-06 Asivi, Llc Treatment of female sexual dysfunction
US6246436B1 (en) * 1997-11-03 2001-06-12 Agilent Technologies, Inc Adjustable gain active pixel sensor
TW542719B (en) * 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury
AU3879299A (en) * 1998-05-07 1999-11-23 Axys Pharmaceuticals, Inc. Genotyping the human udp-glucuronosyltransferase 1 (ugt1) gene
US6403605B1 (en) * 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US6448003B1 (en) * 1998-06-10 2002-09-10 Dna Sciences Laboratories, Inc. Genotyping the human phenol sulfotransferbase 2 gene STP2
US6407117B1 (en) * 1998-06-18 2002-06-18 The George Washington University Method of administering camptothecin compounds for the treatment of cancer with reduced side effects
US6319678B1 (en) * 1998-06-26 2001-11-20 Panvera Corporation Process for glucuronidation screening
US6586175B1 (en) * 1998-07-28 2003-07-01 Dna Sciences Laboratories, Inc. Genotyping the human UDP-glucuronosyltransferase 2B7 (UGT2B7) gene
UA67802C2 (ru) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ПЕРОРАЛЬНОГО ПРИМЕНЕНИЯ С КОНТРОЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ ИНГИБИТОРА цГМФ ФДЭ-5 (ВАРИАНТЫ), СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СПОСОБ ЛЕЧЕНИЯ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ
US6395481B1 (en) * 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter
WO2000066114A1 (en) 1999-04-30 2000-11-09 Lilly Icos Llc Treatment of female arousal disorder
US6632419B2 (en) * 1999-05-04 2003-10-14 Aradigm Corporation Increasing libido in humans via acute testosterone administration
US6428769B1 (en) * 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
EP1207902A2 (de) 1999-06-17 2002-05-29 Pharmacia AB VERWENDUNG VON WACHSTUMSHORMON (hGH) ZUR THERAPIE SEXUELLER FUNKTIONSSTÖRUNGEN
RU2180591C2 (ru) 1999-12-24 2002-03-20 Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ Средство для лечения сексуальных дисфункций у мужчин
DE10016548A1 (de) * 2000-04-03 2001-10-11 Bayer Ag Polyurethan-Dispersionen
US6313172B1 (en) 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6242436B1 (en) * 2000-06-15 2001-06-05 William Charles Llewellyn Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans
AU2001281930A1 (en) * 2000-07-14 2002-01-30 F.Hoffmann-La Roche Ag Method for detecting pre-disposition to hepatotoxicity
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20030139384A1 (en) 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
CA2746787A1 (en) 2000-08-30 2002-03-07 Unimed Pharmaceuticals, Llc. Method of increasing testosterone and related steroid concentrations in women
CA2426666A1 (en) 2000-09-29 2002-04-04 Solvay Pharmaceuticals B.V. Ion-strength independent sustained release pharmaceutical formulation
US20060287335A1 (en) * 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
CN100374575C (zh) * 2000-12-12 2008-03-12 第一化学药品株式会社 评估施用自身或者其代谢中间物被ugt1a1酶代谢的化合物引起严重毒性的方法
US20020107230A1 (en) 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
DE10100238A1 (de) * 2001-01-05 2002-08-22 Hannover Med Hochschule Verfahren zur Vorhersage des Gefährdungspotentials für Karzinomerkrankungen und entzündliche Darmerkrankungen und zugehörige Tests
US20030099960A1 (en) * 2001-01-26 2003-05-29 The University Of Chicago Compositions and methods for optimizing UGT2B7 substrate dosings and for predicting UGT2B7 substrate toxicity
WO2002069906A2 (en) * 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
NZ527012A (en) * 2001-03-28 2005-03-24 Pfizer N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors for FSAD
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US20030022875A1 (en) 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20040203034A1 (en) * 2003-01-03 2004-10-14 The University Of Chicago Optimization of cancer treatment with irinotecan
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
MXPA06000623A (es) * 2003-07-16 2006-04-11 Pfizer Tratamiento de la disfuncion sexual.
DK1530965T3 (da) * 2003-11-11 2006-07-17 Mattern Udo Kontrolleret frigivelsesleveringssystem til nasal applikation
WO2005094827A1 (en) 2004-03-30 2005-10-13 Kestrel Pharmaceuticals Inc. Methods for treating sexual dysfunction
WO2005102342A1 (en) 2004-04-22 2005-11-03 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders ii
PL1750766T3 (pl) * 2004-05-11 2013-12-31 Eb Ip Lybrido B V Preparaty farmaceutyczne i ich zastosowania do leczenia zaburzeń seksualnych u kobiet
CA2604431A1 (en) * 2005-04-13 2006-10-26 Unimed Pharmaceuticals, Inc. Method of increasing testosterone and related steroid concentrations in women
WO2006127057A1 (en) 2005-05-24 2006-11-30 Lyle Corporate Drvelopment, Inc. Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction
US8067399B2 (en) * 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
WO2007054791A2 (en) 2005-11-08 2007-05-18 L'oréal Androgen glucuronides as markers of androgenic activity
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
ME02275B (me) 2007-11-28 2016-02-20 Ucb Pharma Gmbh Polimorfni oblik rotigotina

Also Published As

Publication number Publication date
HRP20191544T1 (hr) 2019-11-29
CY1122051T1 (el) 2020-10-14
CN103083325B (zh) 2017-08-11
EA021540B1 (ru) 2015-07-30
CA2629364A1 (en) 2007-05-18
US20160213683A1 (en) 2016-07-28
WO2007055563A3 (en) 2007-09-07
KR20170029011A (ko) 2017-03-14
NZ567963A (en) 2012-04-27
ME03499B (me) 2020-04-20
EP1965802A2 (en) 2008-09-10
EP1790343A1 (en) 2007-05-30
JP2013241463A (ja) 2013-12-05
US9333203B2 (en) 2016-05-10
US9737548B2 (en) 2017-08-22
NO20170799A1 (no) 2008-07-31
IL191280A (en) 2016-02-29
EA200801310A1 (ru) 2009-04-28
AU2006312373B2 (en) 2013-01-10
HUE045846T2 (hu) 2020-01-28
NO20170800A1 (no) 2008-07-31
BRPI0618385A2 (pt) 2011-08-30
JP2009515875A (ja) 2009-04-16
US20090306026A1 (en) 2009-12-10
NO20082703L (no) 2008-07-31
KR20150110829A (ko) 2015-10-02
EP1965802B1 (en) 2019-06-05
ZA200903527B (en) 2010-04-28
EA034539B1 (ru) 2020-02-18
KR20140070656A (ko) 2014-06-10
ZA200804443B (en) 2009-10-28
PT1965802T (pt) 2019-09-19
ES2744206T3 (es) 2020-02-24
IL191280A0 (en) 2009-08-03
UA112406C2 (uk) 2016-09-12
AU2006312373A1 (en) 2007-05-18
CA2629364C (en) 2013-07-09
US20170042911A1 (en) 2017-02-16
DK1965802T3 (da) 2019-09-16
KR20080084943A (ko) 2008-09-22
PL1965802T3 (pl) 2020-01-31
JP5959483B2 (ja) 2016-08-02
WO2007055563A2 (en) 2007-05-18
SI1965802T1 (sl) 2019-10-30
CN103083325A (zh) 2013-05-08
NO343941B1 (no) 2019-07-22
KR20160128466A (ko) 2016-11-07
UA97101C2 (ru) 2012-01-10
RS59268B1 (sr) 2019-10-31
NO342986B1 (no) 2018-09-17
CN101346143A (zh) 2009-01-14
LT1965802T (lt) 2019-09-10
HK1128226A1 (en) 2009-10-23
CN101346143B (zh) 2013-01-30

Similar Documents

Publication Publication Date Title
EA200801310A1 (ru) Фармацевтические препараты и их применение при лечении половой дисфункции у женщин
ZA200703002B (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
MY145439A (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
EA201370208A1 (ru) Формы рифаксимина и их применение
BRPI0510094A (pt) uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos
EA201000865A1 (ru) Комбинация ингибиторов протеинтирозинфосфатазы и гормона роста человека, предназначенная для лечения атрофии мышц и родственных нарушений
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
CY1105082T1 (el) Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας
CY1114448T1 (el) Φαρμακευτικες συνθεσεις και χρηση αυτων στην αγωγη της γυναικειας σεξουαλικης δυσλειτουργιας
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
EA201791669A2 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
MX2008002293A (es) Uso novedoso de compuestos peptidicos para tratar dolor muscular.
UA85471C2 (ru) Применение оксикодона для лечения висцеральной боли
EA200700427A1 (ru) Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
NO20071585L (no) Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
MX2007005590A (es) Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
EA200601074A1 (ru) Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
EA201300421A1 (ru) Комбинированная терапия для лечения инфекции hcv
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
EA201200428A1 (ru) Композиция и способ для лечения ожирения
EA200501310A1 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения боли
MXPA05011233A (es) Vectores peptidicos.
EA200701584A1 (ru) Органические соединения, применяемые для лечения болезни альцгеймера, их применение и способ получения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM